Engineering Immune Precision In Situ: A Protein-Based Approach to CAR Conversion
Time: 1:30 pm
day: Day Two
Details:
- Introducing the iCAR paradigm: using engineered proteins to transform immune cells into CAR effectors inside the patient—without gene editing or viral vectors
- Demonstrating the systemic delivery of recombinant iCAR-NK PD-L1 protein to generate in vivo CAR-NK cells targeting PD-L1+ tumors in humanized models
- Outlining our next step: dual iCAR-NK/T protein targeting TROP2 to broaden efficacy across diverse solid tumor landscapes